FDA has approved Wegovy for this, in the words of each label below. ESSENCE (Semaglutide): A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%. ClinicalTrials.gov lists 73 trials of these medicines on it: 13 with posted results and 9 recruiting now.
Read from the registry and PubMed every day. The newest update here is Oct 30, 2026.
The approved use, word for word from each current label.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 800 people · Better than the comparison · Placebo-controlled randomized trial
A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%.
Tirzepatide · 190 people · Better than the comparison · Placebo-controlled randomized trial
A Phase 2 trial. MASH resolved without worse fibrosis in 62% on 15 mg against 10% on placebo. Fibrosis improved by a stage in 51% against 30%.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 33 | 7 | 3 |
| Liraglutide | 11 | 0 | 0 |
| Exenatide | 6 | 4 | 0 |
| Pemvidutide | 6 | 0 | 1 |
| Survodutide | 5 | 1 | 2 |
| Dulaglutide | 4 | 0 | 0 |
| Tirzepatide | 4 | 1 | 2 |
| Mazdutide | 3 | 0 | 1 |
| VK2735 | 1 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide | Phase 2/3 | 92 | Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57. |
| TEALTreating PCOS With Semaglutide vs Active Lifestyle Intervention | Semaglutide | Phase 2/3 | 60 | Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84. |
| NAFLDRole of Exenatide in NASH-a Pilot Study | Exenatide | Phase 2/3 | 8 | On ClinicalTrials.gov |
| NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease | Exenatide | Phase 4 | 24 | On ClinicalTrials.gov |
| WAYFINDStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Semaglutide | Phase 2 | 457 | Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups (percentage of participants), Week 72. SEMA + CILO/FIR FDC: 13.7; PTM SEMA + PTM CILO/FIR: 8.3. |
| NCT02970942Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. | Semaglutide | Phase 2 | 320 | Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No) (Percentage of participants), After 72 weeks, Yes. Semaglutide 0.1 mg: 40.4; Semaglutide 0.2 mg: 35.6; Semaglutide 0.4 mg: 58.9; Placebo: 17.2. |
| NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Survodutide | Phase 2 | 295 | Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment (Percentage of participants), At baseline and at 48 weeks.. Survodutide 2.4 mg - Actual Maintenance Treatment: 38.7; Survodutide 4.8 mg - Actual Maintenance Treatment: 63.8; Survodutide 6.0 mg - Actual Maintenance Treatment: 55.8; Placebo - Actual Maintenance Treatment: 15.2. |
| SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Tirzepatide | Phase 2 | 190 | Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology (Percentage of participants), Week 52. 5 mg Tirzepatide: 51.84; 10 mg Tirzepatide: 63.13; 15 mg Tirzepatide: 73.92; Placebo: 12.62. |
| NCT04944992A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Semaglutide | Phase 2 | 145 | Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks (Percent Reduction), Baseline and up to ~24 Weeks. Efinopegdutide: 72.7; Semaglutide: 42.3. |
| NCT03987074Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | Semaglutide | Phase 2 | 109 | Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) (percentage of participants), First dose date up to Week 24 plus 30 days. Semaglutide: 81.0; Semaglutide + Firsocostat 20 mg: 86.4; Semaglutide + Cilofexor 30 mg: 81.8; Semaglutide + Cilofexor 100 mg: 72.7; Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg: 90.5. |
| NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Semaglutide | Phase 2 | 71 | Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks (Percentage of participants), Week 48. Semaglutide 2.4 mg: 10.6; Placebo: 29.2. |
| NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide | Phase 2 | 51 | On ClinicalTrials.gov |
| NCT00529204Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease | Exenatide | Phase 2 | 1 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
Meta-analysis · Medicine (Baltimore) · Oct 1, 2026 · Alfawaz M et al.
Randomized trial · Diabetes Obes Metab · Aug 17, 2026 · Miyake T et al. · cited by 1
Meta-analysis · Hepatol Int · Jul 27, 2026 · Sun SP et al.
Randomized trial · Lancet Gastroenterol Hepatol · Jul 21, 2026 · Noureddin M et al.
Randomized trial · Lancet Gastroenterol Hepatol · Jul 15, 2026 · Loomba R et al. · cited by 1
Meta-analysis · Medicine (Baltimore) · Jul 1, 2026 · Khan S et al.
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
ESSENCE (Semaglutide, 800 people): A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%.
Yes: Wegovy. Wegovy's label: for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy is the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.
Semaglutide, with 33 registered trials on it, then Liraglutide with 11. More trials do not mean better results: read what each posted.
9 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.